• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

MiR-30a-5p抑制人上尿路尿路上皮癌细胞的上皮-间质转化并上调紧密连接蛋白Claudin-5的表达。

MiR-30a-5p Inhibits Epithelial-to-Mesenchymal Transition and Upregulates Expression of Tight Junction Protein Claudin-5 in Human Upper Tract Urothelial Carcinoma Cells.

作者信息

Chung Yueh-Hua, Li Sung-Chou, Kao Ying-Hsien, Luo Hao-Lun, Cheng Yuan-Tso, Lin Pey-Ru, Tai Ming-Hong, Chiang Po-Hui

机构信息

Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung 80424, Taiwan.

Genomics and Proteomics Core Laboratory, Department of Medical Research, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83301, Taiwan.

出版信息

Int J Mol Sci. 2017 Aug 22;18(8):1826. doi: 10.3390/ijms18081826.

DOI:10.3390/ijms18081826
PMID:28829370
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5578210/
Abstract

UNLABELLED

The involvement of microRNAs (miRNAs) in cancer development and their potential as prognostic biomarkers are becoming increasingly known. However, the signature of miRNAs and their regulatory roles in tumorigenesis of upper tract urothelial carcinoma (UTUC) remain to be elucidated. This study aimed to profile the miRNA expression pattern in UTUC tumor tissues and identify candidate miRNAs with prognostic and/or therapeutic functions.

METHODS AND RESULTS

We collected 22 UTUC tissue and adjacent normal tissues samples from patients who underwent nephroureterectomy. The miRNAs signatures of three selected UTUC samples using next-generation sequencing showed that miR-30a-5p was significantly downregulated in UTUC tumors compared to adjacent normal tissues. The differentially-expressed miRNAs were specifically validated by quantitative real-time polymerase chain reaction. In addition, the miRNA expression signatures were analyzed with the transcriptome profile characterized by microarray. Further in vitro studies indicated that overexpression of miR-30a-5p significantly suppressed proliferation, migration, and epithelial-to-mesenchymal transition (EMT) in cultured BFTC-909 UTUC cells As a potential target gene of miR-30a-5p in the tight junction pathway suggested by the pathway enrichment analysis, the reduced expression of tight junction protein claudin-5 in UTUC cells was demonstrated to be upregulated by miR-30a-5p genetic delivery.

CONCLUSIONS

Taken together, our findings demonstrated that miR-30a-5p inhibits proliferation, metastasis, and EMT, and upregulates the expression of tight junction claudin-5 in UTUC cells. Thus, miR-30a-5p may provide a promising therapeutic strategy for UTUC treatment.

摘要

未标记

微小RNA(miRNA)参与癌症发展及其作为预后生物标志物的潜力日益为人所知。然而,miRNA的特征及其在上尿路尿路上皮癌(UTUC)肿瘤发生中的调控作用仍有待阐明。本研究旨在分析UTUC肿瘤组织中的miRNA表达模式,并鉴定具有预后和/或治疗功能的候选miRNA。

方法与结果

我们收集了22例接受肾输尿管切除术患者的UTUC组织和相邻正常组织样本。使用下一代测序对三个选定的UTUC样本进行miRNA特征分析,结果显示与相邻正常组织相比,miR-30a-5p在UTUC肿瘤中显著下调。通过定量实时聚合酶链反应对差异表达的miRNA进行了特异性验证。此外,利用微阵列表征的转录组图谱分析了miRNA表达特征。进一步的体外研究表明,miR-30a-5p的过表达显著抑制了培养的BFTC-909 UTUC细胞的增殖、迁移和上皮-间质转化(EMT)。通路富集分析提示紧密连接通路中miR-30a-5p的潜在靶基因,通过miR-30a-5p基因传递证实UTUC细胞中紧密连接蛋白claudin-5的表达降低得到上调。

结论

综上所述,我们的研究结果表明miR-30a-5p抑制UTUC细胞的增殖、转移和EMT,并上调紧密连接claudin-5的表达。因此,miR-30a-5p可能为UTUC治疗提供一种有前景的治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee5c/5578210/087ccb8f406b/ijms-18-01826-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee5c/5578210/c12da60ecfa1/ijms-18-01826-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee5c/5578210/9518b604b7e0/ijms-18-01826-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee5c/5578210/c481c228d5d7/ijms-18-01826-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee5c/5578210/f5e6bc397681/ijms-18-01826-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee5c/5578210/9af705437664/ijms-18-01826-g005a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee5c/5578210/25dd7bd1df61/ijms-18-01826-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee5c/5578210/a4df0f45cdf8/ijms-18-01826-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee5c/5578210/087ccb8f406b/ijms-18-01826-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee5c/5578210/c12da60ecfa1/ijms-18-01826-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee5c/5578210/9518b604b7e0/ijms-18-01826-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee5c/5578210/c481c228d5d7/ijms-18-01826-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee5c/5578210/f5e6bc397681/ijms-18-01826-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee5c/5578210/9af705437664/ijms-18-01826-g005a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee5c/5578210/25dd7bd1df61/ijms-18-01826-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee5c/5578210/a4df0f45cdf8/ijms-18-01826-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee5c/5578210/087ccb8f406b/ijms-18-01826-g008.jpg

相似文献

1
MiR-30a-5p Inhibits Epithelial-to-Mesenchymal Transition and Upregulates Expression of Tight Junction Protein Claudin-5 in Human Upper Tract Urothelial Carcinoma Cells.MiR-30a-5p抑制人上尿路尿路上皮癌细胞的上皮-间质转化并上调紧密连接蛋白Claudin-5的表达。
Int J Mol Sci. 2017 Aug 22;18(8):1826. doi: 10.3390/ijms18081826.
2
MicroRNA-145 suppresses cell migration and invasion in upper tract urothelial carcinoma by targeting ARF6.微小 RNA-145 通过靶向 ARF6 抑制上尿路尿路上皮癌中的细胞迁移和侵袭。
FASEB J. 2020 Apr;34(4):5975-5992. doi: 10.1096/fj.201902555R. Epub 2020 Feb 20.
3
p53/miR-30a-5p/ SOX4 feedback loop mediates cellular proliferation, apoptosis, and migration of non-small-cell lung cancer.p53/miR-30a-5p/SOX4 反馈环介导非小细胞肺癌细胞的增殖、凋亡和迁移。
J Cell Physiol. 2019 Dec;234(12):22884-22895. doi: 10.1002/jcp.28851. Epub 2019 May 23.
4
MiR-26a-5p as a useful therapeutic target for upper tract urothelial carcinoma by regulating WNT5A/β-catenin signaling.miR-26a-5p 通过调控 WNT5A/β-catenin 信号通路成为上尿路上皮癌的一个有价值的治疗靶点。
Sci Rep. 2022 Apr 28;12(1):6955. doi: 10.1038/s41598-022-08091-6.
5
MicroRNA-30a increases tight junction protein expression to suppress the epithelial-mesenchymal transition and metastasis by targeting Slug in breast cancer.微小RNA-30a通过靶向乳腺癌中的Slug增加紧密连接蛋白表达,从而抑制上皮-间质转化和转移。
Oncotarget. 2016 Mar 29;7(13):16462-78. doi: 10.18632/oncotarget.7656.
6
Mechanism of Low Expression of miR-30a-5p on Epithelial-Mesenchymal Transition and Metastasis in Ovarian Cancer.miR-30a-5p 在卵巢癌细胞上皮间质转化及转移中低表达的机制。
DNA Cell Biol. 2019 Apr;38(4):341-351. doi: 10.1089/dna.2018.4396. Epub 2019 Mar 6.
7
Overexpression of microRNA-30a-5p inhibits liver cancer cell proliferation and induces apoptosis by targeting MTDH/PTEN/AKT pathway.微小RNA-30a-5p的过表达通过靶向MTDH/PTEN/AKT通路抑制肝癌细胞增殖并诱导其凋亡。
Tumour Biol. 2016 May;37(5):5885-95. doi: 10.1007/s13277-015-4456-1. Epub 2015 Nov 21.
8
Expression of miRNAs involved in angiogenesis, tumor cell proliferation, tumor suppressor inhibition, epithelial-mesenchymal transition and activation of metastasis in bladder cancer.膀胱癌中涉及血管生成、肿瘤细胞增殖、肿瘤抑制物抑制、上皮-间充质转化和转移激活的 miRNA 的表达。
J Urol. 2012 Aug;188(2):615-23. doi: 10.1016/j.juro.2012.03.122. Epub 2012 Jun 15.
9
MiR-30a-5p Suppresses Tumor Metastasis of Human Colorectal Cancer by Targeting ITGB3.微小RNA-30a-5p通过靶向整合素β3抑制人结直肠癌的肿瘤转移。
Cell Physiol Biochem. 2016;39(3):1165-76. doi: 10.1159/000447823. Epub 2016 Aug 31.
10
miR-30a-5p Inhibits Epithelial-to-Mesenchymal Transition by Targeting CDK6 in Nasal Polyps.miR-30a-5p 通过靶向 CDK6 抑制鼻息肉中的上皮间质转化。
Am J Rhinol Allergy. 2021 Mar;35(2):152-163. doi: 10.1177/1945892420939814. Epub 2020 Jul 5.

引用本文的文献

1
Large-Scale Isolation of Milk Exosomes for Skincare.用于护肤品的大规模牛奶外泌体分离
Pharmaceutics. 2024 Jul 11;16(7):930. doi: 10.3390/pharmaceutics16070930.
2
miR-194-3p regulates epithelial-mesenchymal transition in embryonic epicardial cells via p120/β-catenin signaling.miR-194-3p 通过 p120/β-catenin 信号通路调控胚胎心外膜细胞的上皮间质转化。
Acta Biochim Biophys Sin (Shanghai). 2024 May 25;56(5):717-729. doi: 10.3724/abbs.2024051.
3
Genetic Interference of FGFR3 Impedes Invasion of Upper Tract Urothelial Carcinoma Cells by Alleviating RAS/MAPK Signal Activity.

本文引用的文献

1
MiR-30a-5p Overexpression May Overcome EGFR-Inhibitor Resistance through Regulating PI3K/AKT Signaling Pathway in Non-small Cell Lung Cancer Cell Lines.miR-30a-5p过表达可能通过调控非小细胞肺癌细胞系中的PI3K/AKT信号通路克服表皮生长因子受体抑制剂耐药性。
Front Genet. 2016 Nov 15;7:197. doi: 10.3389/fgene.2016.00197. eCollection 2016.
2
Claudin-5, -7, and -18 suppress proliferation mediated by inhibition of phosphorylation of Akt in human lung squamous cell carcinoma.Claudin-5、-7 和 -18 通过抑制人肺鳞癌细胞中 Akt 的磷酸化来抑制增殖。
Biochim Biophys Acta Mol Cell Res. 2017 Feb;1864(2):293-302. doi: 10.1016/j.bbamcr.2016.11.018. Epub 2016 Nov 21.
3
成纤维细胞生长因子受体 3 的基因干扰通过减轻 RAS/MAPK 信号活性阻碍上尿路尿路上皮癌细胞的侵袭。
Int J Mol Sci. 2023 Jan 16;24(2):1776. doi: 10.3390/ijms24021776.
4
MiR-26a-5p as a useful therapeutic target for upper tract urothelial carcinoma by regulating WNT5A/β-catenin signaling.miR-26a-5p 通过调控 WNT5A/β-catenin 信号通路成为上尿路上皮癌的一个有价值的治疗靶点。
Sci Rep. 2022 Apr 28;12(1):6955. doi: 10.1038/s41598-022-08091-6.
5
MicroRNA Signatures in the Upper Urinary Tract Urothelial Carcinoma Scenario: Ready for the Game Changer?上尿路尿路上皮癌中的 microRNA 特征:准备好改变游戏规则了吗?
Int J Mol Sci. 2022 Feb 26;23(5):2602. doi: 10.3390/ijms23052602.
6
The MicroRNA Prediction Models as Ancillary Diagnosis Biomarkers for Urothelial Carcinoma in Patients With Chronic Kidney Disease.微小RNA预测模型作为慢性肾脏病患者尿路上皮癌辅助诊断生物标志物
Front Med (Lausanne). 2021 Oct 1;8:726214. doi: 10.3389/fmed.2021.726214. eCollection 2021.
7
Noncoding RNAs Associated with Therapeutic Resistance in Pancreatic Cancer.与胰腺癌治疗耐药相关的非编码RNA
Biomedicines. 2021 Mar 7;9(3):263. doi: 10.3390/biomedicines9030263.
8
Involvement of miR-30a-5p and miR-30d in Endothelial to Mesenchymal Transition and Early Osteogenic Commitment under Inflammatory Stress in HUVEC.miR-30a-5p 和 miR-30d 在炎症应激下 HUVEC 中的内皮向间充质转化和早期成骨定向中的作用。
Biomolecules. 2021 Feb 5;11(2):226. doi: 10.3390/biom11020226.
9
miR-331 inhibits CLDN2 expression and may alleviate the vascular endothelial injury induced by sepsis.微小RNA-331抑制紧密连接蛋白2的表达,并可能减轻脓毒症诱导的血管内皮损伤。
Exp Ther Med. 2020 Aug;20(2):1343-1352. doi: 10.3892/etm.2020.8854. Epub 2020 Jun 10.
10
Role of Axis in Neonatal Hyperoxic Lung Injury.轴突在新生鼠高氧肺损伤中的作用。
Oxid Med Cell Longev. 2019 Oct 22;2019:8327486. doi: 10.1155/2019/8327486. eCollection 2019.
MiR-30a-5p Suppresses Tumor Metastasis of Human Colorectal Cancer by Targeting ITGB3.
微小RNA-30a-5p通过靶向整合素β3抑制人结直肠癌的肿瘤转移。
Cell Physiol Biochem. 2016;39(3):1165-76. doi: 10.1159/000447823. Epub 2016 Aug 31.
4
MiR-30a increases cisplatin sensitivity of gastric cancer cells through suppressing epithelial-to-mesenchymal transition (EMT).微小RNA-30a通过抑制上皮-间质转化(EMT)增加胃癌细胞对顺铂的敏感性。
Eur Rev Med Pharmacol Sci. 2016 May;20(9):1733-9.
5
miR-30a can inhibit DNA replication by targeting RPA1 thus slowing cancer cell proliferation.微小RNA-30a可通过靶向复制蛋白A1抑制DNA复制,从而减缓癌细胞增殖。
Biochem J. 2016 Jul 15;473(14):2131-9. doi: 10.1042/BCJ20160177. Epub 2016 May 17.
6
MiR-30a and miR-205 are downregulated in hypoxia and modulate radiosensitivity of prostate cancer cells by inhibiting autophagy via TP53INP1.MiR-30a和miR-205在缺氧条件下表达下调,并通过TP53INP1抑制自噬来调节前列腺癌细胞的放射敏感性。
Eur Rev Med Pharmacol Sci. 2016 Apr;20(8):1501-8.
7
Expression of Estrogen Receptor Beta Predicts Oncologic Outcome of pT3 Upper Urinary Tract Urothelial Carcinoma Better Than Aggressive Pathological Features.雌激素受体β的表达比侵袭性病理特征更能预测pT3上尿路尿路上皮癌的肿瘤学结局。
Sci Rep. 2016 Apr 7;6:24263. doi: 10.1038/srep24263.
8
MiR-30a-5p/UBE3C axis regulates breast cancer cell proliferation and migration.miR-30a-5p/UBE3C 轴调控乳腺癌细胞的增殖和迁移。
Biochem Biophys Res Commun. 2019 Aug 27;516(3):1013-1018. doi: 10.1016/j.bbrc.2016.03.069. Epub 2016 Mar 18.
9
Microarray Study of Pathway Analysis Expression Profile Associated with MicroRNA-29a with Regard to Murine Cholestatic Liver Injuries.关于小鼠胆汁淤积性肝损伤,与微小RNA-29a相关的通路分析表达谱的微阵列研究。
Int J Mol Sci. 2016 Mar 1;17(3):324. doi: 10.3390/ijms17030324.
10
MicroRNA-30a increases tight junction protein expression to suppress the epithelial-mesenchymal transition and metastasis by targeting Slug in breast cancer.微小RNA-30a通过靶向乳腺癌中的Slug增加紧密连接蛋白表达,从而抑制上皮-间质转化和转移。
Oncotarget. 2016 Mar 29;7(13):16462-78. doi: 10.18632/oncotarget.7656.